EG-30: clinical phase drug for AMD and Glaucoma
EG-30 – the highlights:
· Excellent safety profile in healthy volunteers and glaucoma patients
• Low systemic exposure
• No increase in IOP in glaucoma patients treated with EG-30 for 16days (eye drops)
· Extensive safety and efficacy preclinical package:
• EG-30 inhibit the formation of amyloid beta oligomers and serve as a cytoprotectant agent
• Efficacy in dry AMD and glaucoma animal models
• Safety and toxicology including 6 months toxicology studies in rabbits and monkeys
· An FDA approved development path allowing a single confirmatory study for FDA approval of EG-30 for both glaucoma and dry AMD
· New derivatives for Alzheimer treatment
1586128566.jpg)